Casi Pharmaceuticals (CASI) announced the appointment of David Cory as CEO and a member of the board of directors. Wei-Wu He will step down as the CEO and will remain as executive chairman of the board of directors. Most recently, Cory was CEO and director of LIB Therapeutics which completed Phase 3 registration-enabling trials for its lead cardiovascular disease program and filed for regulatory approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.